EMAIL THIS PAGE TO A FRIEND

Bioorganic & medicinal chemistry letters

N-Heteroaryl glycinamides and glycinamines as potent NPY5 antagonists.


PMID 21782430

Abstract

Subtype specific ligands are needed to evaluate the therapeutic potential of modulating the brain's neuropeptide Y system. The benzothiazepine glycinamide 1a was identified as an NPY5 antagonist lead. While having acceptable solubility, the compound was found to suffer from high clearance and poor exposure. Optimization efforts are described targeting improvements in potency, microsomal stability, and PK properties. The low microsomal stability and poor PK properties were addressed through the optimization of the sulfonyl urea and replacement of the benzothiazepinone with other N-heteroaryl glycinamides. For example, the analogous benzoxazine glycinamide 2e has improvements in both affinity (human Y5 K(i) 4 nM vs 1a 27 nM) and microsomal stability (human CL(int) 2.5 L/min vs 1a 35L/min). However the brain penetration (B/P 43/430 nM at 10 mg/kg PO) remained an unresolved issue. Further optimization by decreasing the hydrogen bond donating properties and PSA provided potent and brain penetrant NPY5 antagonists such as 5f (human Y5 K(i) 9 nM, B/P 520/840 nM 10 mg/kg PO).

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

G6104
Glycinamide hydrochloride, 98%
C2H6N2O · HCl
50070
Glycinamide hydrochloride, ≥99.0% (AT)
C2H6N2O · HCl